| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
|
N Engl J Med
|
2006
|
17.08
|
|
2
|
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.
|
Nat Genet
|
2010
|
4.96
|
|
3
|
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
|
Breast Cancer Res Treat
|
2008
|
4.84
|
|
4
|
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
|
J Clin Oncol
|
2011
|
3.71
|
|
5
|
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Am J Hum Genet
|
2008
|
3.41
|
|
6
|
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
PLoS Genet
|
2013
|
2.39
|
|
7
|
Nasal intermittent mandatory ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a randomized, controlled, prospective study.
|
J Pediatr
|
2007
|
2.36
|
|
8
|
Diabetes mellitus and breast cancer.
|
Lancet Oncol
|
2005
|
2.34
|
|
9
|
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.
|
Hum Mol Genet
|
2009
|
2.13
|
|
10
|
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
|
Proc Natl Acad Sci U S A
|
2006
|
1.99
|
|
11
|
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
|
Cancer Res
|
2010
|
1.90
|
|
12
|
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
|
J Clin Oncol
|
2013
|
1.79
|
|
13
|
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
|
J Clin Oncol
|
2008
|
1.78
|
|
14
|
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
|
Lancet Oncol
|
2013
|
1.70
|
|
15
|
Pregnancy-associated breast cancer.
|
Isr Med Assoc J
|
2008
|
1.53
|
|
16
|
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
|
Hum Mol Genet
|
2011
|
1.51
|
|
17
|
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
|
J Neurooncol
|
2011
|
1.17
|
|
18
|
Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients.
|
Cancer
|
2006
|
1.13
|
|
19
|
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
|
PLoS Biol
|
2011
|
1.12
|
|
20
|
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
|
Breast Cancer Res Treat
|
2010
|
1.10
|
|
21
|
KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer.
|
Clin Cancer Res
|
2011
|
1.07
|
|
22
|
Association between diabetes mellitus and adverse characteristics of breast cancer at presentation.
|
Eur J Cancer
|
2006
|
1.04
|
|
23
|
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.01
|
|
24
|
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
|
Clin Cancer Res
|
2013
|
0.99
|
|
25
|
First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study.
|
Oncology
|
2012
|
0.96
|
|
26
|
Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
|
Cancer
|
2008
|
0.93
|
|
27
|
Motivation for giving birth after breast cancer.
|
Psychooncology
|
2005
|
0.93
|
|
28
|
The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
|
Breast Cancer Res Treat
|
2011
|
0.91
|
|
29
|
Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer.
|
J Surg Oncol
|
2008
|
0.91
|
|
30
|
Epigenetic silencing of the tumor suppressor klotho in human breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.90
|
|
31
|
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
|
Hum Mol Genet
|
2011
|
0.89
|
|
32
|
The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.
|
Fam Cancer
|
2009
|
0.89
|
|
33
|
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.89
|
|
34
|
Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
|
Breast Cancer Res Treat
|
2010
|
0.86
|
|
35
|
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
|
J Clin Oncol
|
2011
|
0.84
|
|
36
|
Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
|
Fam Cancer
|
2008
|
0.83
|
|
37
|
Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients.
|
Am J Clin Oncol
|
2009
|
0.81
|
|
38
|
Association between very young age and adverse characteristics of breast cancer at presentation amongst Israeli women.
|
Am J Clin Oncol
|
2011
|
0.80
|
|
39
|
Breast conservation after neoadjuvant chemotherapy.
|
Ann Surg Oncol
|
2005
|
0.80
|
|
40
|
Male breast carcinoma in Israel: higher incident but possibly prognosis in Ashkenazi Jews.
|
Cancer
|
2002
|
0.79
|
|
41
|
Exploring the link between MORF4L1 and risk of breast cancer.
|
Breast Cancer Res
|
2011
|
0.79
|
|
42
|
Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
|
Isr Med Assoc J
|
2007
|
0.79
|
|
43
|
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
|
Cancer Treat Rev
|
2005
|
0.78
|
|
44
|
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
|
Breast Cancer Res Treat
|
2011
|
0.78
|
|
45
|
The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.
|
Fam Cancer
|
2012
|
0.78
|
|
46
|
Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer.
|
Breast Cancer Res Treat
|
2014
|
0.78
|
|
47
|
[Body weight, nutritional factors and physical activity--their influence on prognosis after breast cancer diagnosis].
|
Harefuah
|
2006
|
0.78
|
|
48
|
Evidence for a link between TNFRSF11A and risk of breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.77
|
|
49
|
[Hormone replacement therapy in breast cancer survivors: the Israeli Society for Clinical Oncology and Radiotherapy policy letter].
|
Harefuah
|
2002
|
0.77
|
|
50
|
Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
|
Breast Cancer Res Treat
|
2011
|
0.77
|
|
51
|
SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women.
|
Fam Cancer
|
2008
|
0.76
|
|
52
|
Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
|
Breast Cancer Res Treat
|
2012
|
0.76
|
|
53
|
Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.
|
PLoS One
|
2013
|
0.75
|
|
54
|
The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort.
|
Oncology
|
2014
|
0.75
|
|
55
|
High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
|
Acta Oncol
|
2008
|
0.75
|
|
56
|
[Hormone replacement therapy in breast cancer survivors: the Israeli Society for Clinical Oncology and Radiotherapy policy letter].
|
Harefuah
|
2004
|
0.75
|
|
57
|
Immunosuppressive treatments reduce long-term immunity to smallpox among patients with breast cancer.
|
J Infect Dis
|
2010
|
0.75
|